30 results
CORRESP
CHRS
Coherus Biosciences Inc
7 Oct 14
Correspondence with SEC
12:00am
. As described above, this analysis reflected the Company’s formalized engagement of a lead underwriter by early May 2014 and commencement of initial … of a potential IPO scenario (65%), which reflected the fact that the Company had formalized its engagement of a lead underwriter by early May 2014, commenced
DRS/A
EX-10
CHRS
Coherus Biosciences Inc
24 Sep 14
Draft registration statement (amended)
12:00am
involving drugs, biologics, and medical devices through engagement by its clients, the sponsors of clinical development programs, to perform
S-4/A
8y8lsvxq6ijiwf68y
24 Jul 23
Registration of securities issued in business combination transactions (amended)
4:42pm
S-4
zv2wcs
7 Jul 23
Registration of securities issued in business combination transactions
5:03pm
424B3
uzaoyin8t3
26 Jul 23
Prospectus supplement
4:59pm
8-K
EX-3.1
x5psway7
18 Nov 20
Departure of Directors or Certain Officers
4:06pm
8-K
EX-2.1
ieu85og9u
16 Jun 23
Coherus to Acquire Surface Oncology
7:06am
8-K
EX-2.1
lqj4tj bwskp
22 Jan 24
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in Conference Call Information
8:01am
425
yzrq40
16 Jun 23
Business combination disclosure
7:09am